| 25th Nov 2024 7:00 am |
RNS |
Blenrep combinations accepted for US FDA review |
| 22nd Nov 2024 7:00 am |
RNS |
Japan approves first RSV vaccine for adults 50-59 |
| 19th Nov 2024 3:30 pm |
RNS |
Director/PDMR Shareholding |
| 19th Nov 2024 7:00 am |
RNS |
GLISTEN Trial of Linerixibat Meets Endpoint |
| 14th Nov 2024 7:00 am |
RNS |
GSK announces overall survival results for Blenrep |
| 13th Nov 2024 3:00 pm |
RNS |
Block listing Interim Review |
| 12th Nov 2024 3:30 pm |
RNS |
Director/PDMR Shareholding |
| 11th Nov 2024 3:01 pm |
RNS |
GSK publishes provisional 2025 dividend dates |
| 1st Nov 2024 3:00 pm |
RNS |
Total Voting Rights |
| 30th Oct 2024 2:29 pm |
RNS |
Director/PDMR Shareholding |
| 30th Oct 2024 7:00 am |
RNS |
3rd Quarter Results |
| 24th Oct 2024 7:00 am |
RNS |
New positive Arexvy data in younger adults at risk |
| 17th Oct 2024 3:30 pm |
RNS |
Director/PDMR Shareholding |
| 16th Oct 2024 4:09 pm |
RNS |
Director/PDMR Shareholding |
| 16th Oct 2024 7:00 am |
RNS |
FDA accepts new drug application for gepotidacin |
| 14th Oct 2024 3:30 pm |
RNS |
Director/PDMR Shareholding |
| 14th Oct 2024 7:00 am |
RNS |
Positive results of ANCHOR trials of depemokimab |
| 11th Oct 2024 3:33 pm |
RNS |
Director/PDMR Shareholding |
| 10th Oct 2024 3:30 pm |
RNS |
Director/PDMR Shareholding |
| 9th Oct 2024 5:48 pm |
RNS |
Zantac (ranitidine) litigation settlements |
| 8th Oct 2024 11:45 am |
RNS |
Positive efficacy data of Arexvy over 3 seasons |
| 1st Oct 2024 3:00 pm |
RNS |
Total Voting Rights |
| 24th Sep 2024 3:30 pm |
RNS |
Director/PDMR Shareholding |
| 24th Sep 2024 7:00 am |
RNS |
Positive EU opinion for GSK liquid Menveo vaccine |
| 18th Sep 2024 1:20 pm |
RNS |
Statement: Zantac (ranitidine) litigation |
| 17th Sep 2024 7:00 am |
RNS |
Japan Filing Acceptance: Blenrep Multiple Myeloma |
| 13th Sep 2024 7:00 am |
RNS |
China Breakthrough Therapy Designation for Blenrep |
| 12th Sep 2024 3:30 pm |
RNS |
Director/PDMR Shareholding |
| 12th Sep 2024 7:00 am |
RNS |
Positive mRNA flu vaccine Phase II headline data |
| 11th Sep 2024 5:27 pm |
RNS |
Statement: Zantac (ranitidine) litigation |
| 11th Sep 2024 3:30 pm |
RNS |
Change of Registered Office |
| 11th Sep 2024 7:00 am |
RNS |
Update on phase I/II therapeutic HSV vaccine trial |
| 9th Sep 2024 2:30 pm |
RNS |
Depemokimab late-breaking data presented at ERS |
| 6th Sep 2024 3:30 pm |
RNS |
Director/PDMR Shareholding |
| 6th Sep 2024 7:00 am |
RNS |
Positive Phase III results for Nucala in COPD |
| 2nd Sep 2024 3:00 pm |
RNS |
Total Voting Rights |
| 29th Aug 2024 7:00 am |
RNS |
EMA approval on Arexvy for 50-59 at risk |
| 28th Aug 2024 7:10 am |
RNS |
SENKU Designation for Bepirovirsen in Japan |
| 28th Aug 2024 7:05 am |
RNS |
Nucala approved in Japan for use in CRSwNP |
| 28th Aug 2024 7:00 am |
RNS |
Statement: Zantac (ranitidine) litigation |
